{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:18:02Z","timestamp":1794331082795,"version":"4.9.0"},"reference-count":29,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"unspecified","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bioexcel Therapeutics, Inc.","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,4,24]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Small cell neuroendocrine prostate cancer (SCNC) is a lethal subset of prostate cancer with limited treatment options. Talabostat, an oral small molecule inhibitor of dipeptidyl peptidases (DPP4 and DPP 8\/9) triggers the inflammasome to alert and prime immune cells, leading to induction of interleukin (IL)-18 and IL-1\u00df, bridging innate and adaptive immunity. Talabostat was evaluated in a phase 2 study in combination with pembrolizumab in patients with SCNC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were required to have centrally confirmed histologic evidence of de novo or treatment-emergent SCNC and progression on \u22651 prior line of systemic therapy. Patients received pembrolizumab (200\u2009mg intravenous every 21 days) + BXCL701 0.2\u2009mg orally two times per day for a week, with step-up to 0.3\u2009mg two times per day on days 8\u201314, and 0.3\u2009mg two times per day on days 1\u201314 of subsequent cycles. The primary endpoint was the composite response rate (CRR). Biomarkers including levels of DPP 8\/9 expression and association with clinical outcomes were analyzed in a post hoc fashion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>34 patients were enrolled, including 21 (62%) with visceral metastases. Patients had received a median of 3 prior lines of systemic treatment, including 19 (56%) and 18 (53%) of patients who received prior platinum and taxane chemotherapy, respectively. In the response evaluable subset (n=30), the CRR was 20% (95% CI 7.7% to 38.6%)\u2009and the objective response rate was 13% (95% CI 3.8% to 30.7%). The median duration of objective response was 9.0 months. All responders had tumors with low tumor mutational burden and\/or microsatellite stability. The median radiographic progression-free survival was 2.1 months (95%\u2009CI 1.9 to 4.2). The median overall survival (OS) was 13.7 months (95%\u2009CI 7.0 to unevaluable) and the 12-month OS rate was 54.1% (95% CI 34.2% to 70.3%). The most frequently occurring treatment-related adverse events of any grade severity were fatigue (41%), hypotension (29%), dizziness (21%), pruritus (24%), nausea (15%), and diarrhea (15%). Baseline levels of DPP9 tumor stromal expression were associated with response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Talabostat plus pembrolizumab demonstrates preliminary anti-tumor activity in patients with relapsed SCNC. Further evaluation in a randomized study is warranted to assess the contribution of talabostat in this high-risk disease subset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03910660\">NCT03910660<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014242","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:55:25Z","timestamp":1778504125000},"page":"e014242","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03910660","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03910660","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7003-7982","authenticated-orcid":false,"given":"Rahul","family":"Aggarwal","sequence":"first","affiliation":[{"name":"University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Monk","sequence":"additional","affiliation":[{"name":"Ohio State University James Cancer Hospital, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Northwell Health Cancer Institute, New Hyde Park, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Jones","sequence":"additional","affiliation":[{"name":"Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Linch","sequence":"additional","affiliation":[{"name":"UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Costin","sequence":"additional","affiliation":[{"name":"Center for Cancer Care, White Plains Hospital, White Plains, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital Sutton, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence I","family":"Karsh","sequence":"additional","affiliation":[{"name":"AdventHealth Urology, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P","family":"Petrylak","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Deshpande","sequence":"additional","affiliation":[{"name":"BioXcel Therapeutics, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Borderies","sequence":"additional","affiliation":[{"name":"BioXcel Therapeutics, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoti","family":"Huang","sequence":"additional","affiliation":[{"name":"Duke University, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"BioXcel Therapeutics, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Donkor","sequence":"additional","affiliation":[{"name":"BioXcel Therapeutics, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Tagawa","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2026051105551885000_14.5.e014242.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026051105551885000_14.5.e014242.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00651-2"},{"key":"2026051105551885000_14.5.e014242.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2026051105551885000_14.5.e014242.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.08.011"},{"key":"2026051105551885000_14.5.e014242.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6880"},{"key":"2026051105551885000_14.5.e014242.6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0073"},{"key":"2026051105551885000_14.5.e014242.7","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4045"},{"key":"2026051105551885000_14.5.e014242.8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051105551885000_14.5.e014242.9","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2024.42.16_suppl.3001","article-title":"First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors","volume":"42","author":"Chandana","year":"2024","journal-title":"JCO"},{"key":"2026051105551885000_14.5.e014242.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00340-5"},{"key":"2026051105551885000_14.5.e014242.11","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/s43018-024-00838-6","article-title":"The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1","volume":"5","author":"Romero","year":"2024","journal-title":"Nat Cancer"},{"key":"2026051105551885000_14.5.e014242.12","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1158\/0008-5472.CAN-24-0932","article-title":"YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer","volume":"84","author":"Song","year":"2024","journal-title":"Cancer Res"},{"key":"2026051105551885000_14.5.e014242.13","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-22-3743","article-title":"Immunogenomic Landscape of Neuroendocrine Prostate Cancer","volume":"29","author":"Bhinder","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026051105551885000_14.5.e014242.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.011"},{"key":"2026051105551885000_14.5.e014242.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00524-7"},{"key":"2026051105551885000_14.5.e014242.16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2658","article-title":"SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors","volume":"37","author":"Patel","year":"2019","journal-title":"JCO"},{"key":"2026051105551885000_14.5.e014242.17","doi-asserted-by":"crossref","unstructured":"Talabostat CC . Expert Opin Investig Drugs. 2007;16:17714031. doi:10.1517\/13543784.16.9.1459","DOI":"10.1517\/13543784.16.9.1459"},{"key":"2026051105551885000_14.5.e014242.18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.chembiol.2017.12.013","article-title":"Inhibition of Dpp8\/9 Activates the Nlrp1b Inflammasome","volume":"25","author":"Okondo","year":"2018","journal-title":"Cell Chem Biol"},{"key":"2026051105551885000_14.5.e014242.19","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2229"},{"key":"2026051105551885000_14.5.e014242.20","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1158\/1538-7445.AM2017-2629","article-title":"Abstract 2629: The synergy between BXCL701, a DPP inhibitor, and immune checkpoint inhibitors discovered using AI and Big Data analytics","volume":"77","author":"Rastelli","year":"2017","journal-title":"Cancer Res"},{"key":"2026051105551885000_14.5.e014242.21","doi-asserted-by":"crossref","DOI":"10.3390\/biom14040391","article-title":"DPP Inhibition Enhances the Efficacy of PD-1 Blockade by Remodeling the Tumor Microenvironment in Lewis Lung Carcinoma Model","volume":"14","author":"Lei","year":"2024","journal-title":"Biomolecules"},{"key":"2026051105551885000_14.5.e014242.22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.2021.39.6_suppl.124","article-title":"BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC)","volume":"39","author":"Aggarwal","year":"2021","journal-title":"JCO"},{"key":"2026051105551885000_14.5.e014242.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0872"},{"key":"2026051105551885000_14.5.e014242.24","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"PMID","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026051105551885000_14.5.e014242.25","doi-asserted-by":"crossref","unstructured":"Agarwal V , Trivedi S , Bhatia D , et al . 25\u2005Potential predictive biomarkers for bxcl701 in acute myeloid leukemia (aml). SITC 37th Annual Meeting (SITC 2022) Abstracts; 2022 doi:10.1136\/jitc-2022-SITC2022.0025","DOI":"10.1136\/jitc-2022-SITC2022.0025"},{"key":"2026051105551885000_14.5.e014242.26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov"},{"key":"2026051105551885000_14.5.e014242.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2061"},{"key":"2026051105551885000_14.5.e014242.28","unstructured":"NCCN guidelines version. 2025."},{"key":"2026051105551885000_14.5.e014242.29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI131041"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:55:29Z","timestamp":1778504129000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,11]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2025-014242"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014242","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}